A scoping review of active, participant centred, digital adverse events following immunization (AEFI) surveillance of WHO approved COVID-19 vaccines: A Canadian immunization Research Network study

References

• Kochhar S, Salmon DA. Planning for COVID-19 vaccines safety surveillance. Vaccine. 2020;38(40):6194–28. doi:10.1016/j.vaccine.2020.07.013.
   PubMed Web of Science ®Google Scholar
• Petousis-Harris H. Assessing the safety of COVID-19 vaccines: a primer. Drug Saf. 2020;43(12):1205–10. doi:10.1007/s40264-020-01002-6.
   PubMed Web of Science ®Google Scholar
• Lee GM, Romero JR, Bell BP. Postapproval vaccine safety surveillance for COVID-19 vaccines in the US. JAMA - J Am Med Assoc. 2020;324(19):1937. doi:10.1001/jama.2020.19692.
   PubMed Web of Science ®Google Scholar
• Crawford NW, Clothier H, Hodgson K, Selvaraj G, Easton ML, Buttery JP. Active surveillance for adverse events following immunization. Expert Rev Vaccines. 2014;13(2):265–76. doi:10.1586/14760584.2014.866895.
   PubMed Web of Science ®Google Scholar
• Cashman P, Macartney K, Khandaker G, King C, Gold M, Durrheima DN. Participant-centred active surveillance of adverse events following immunisation: a narrative review. Int Health. 2017;9(3):164–76. doi:10.1093/inthealth/ihx019.
   PubMed Web of Science ®Google Scholar
• Heininger U, Holm K, Caplanusi I, et al. Guide to active vaccine safety surveillance: report of CIOMS working group on vaccine safety – executive summary. Vaccine. 2017;35(32):3917–21. doi:10.1016/j.vaccine.2017.06.033.
   PubMed Web of Science ®Google Scholar
• Whitelaw S, Mamas MA, Topol E, van Spall HGC. Applications of digital technology in COVID-19 pandemic planning and response. Lancet Digit Health. 2020;2(8):e435–e440. doi:10.1016/S2589-7500(20)30142-4.
   PubMedGoogle Scholar
• Du J, Xiang Y, Sankaranarayanapillai M, Zhang M, Wang J, Si Y, Pham HA, Xu H, Chen Y, Tao C. Extracting postmarketing adverse events from safety reports in the vaccine adverse event reporting system (VAERS) using deep learning. J Am Med Inform Assn. 2021;28(7):1393–400. doi:10.1093/jamia/ocab014.
   PubMed Web of Science ®Google Scholar
• Mbunge E, Akinnuwesi B, Fashoto SG, Metfula AS, Mashwama P. A critical review of emerging technologies for tackling COVID-19 pandemic. Hum Behav Emerg Technol. 2021;3(1):25–39. doi:10.1002/hbe2.237.
   PubMedGoogle Scholar
• Odone A, Gianfredi V, Sorbello S, Capraro M, Frascella B, Vigezzi GP, Signorelli C. The use of digital technologies to support vaccination programmes in Europe: state of the art and best practices from experts’ interviews. Vaccines (Basel). 2021;9(10):1126. doi:10.3390/vaccines9101126.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). V-safe after vaccination Health checker. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/vsafe.html.
   Google Scholar
• Levac D, Colquhoun H, O’Brien KK. Scoping studies: advancing the methodology. Implement Sci. 2010;5(1). doi:10.1186/1748-5908-5-69.
   PubMedGoogle Scholar
• Arksey H, O’Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol Theory Pract. 2005;8(1):19–32. doi:10.1080/1364557032000119616.
   Google Scholar
• Tricco AC, Lillie E, Zarin W, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467–73. doi:10.7326/M18-0850.
   PubMed Web of Science ®Google Scholar
• World Health Organization. World Health Organization (WHO): 10 vaccines approved for use by WHO. https://covid19.trackvaccines.org/agency/who/.
   Google Scholar
• Covidence. Covidence systematic review software, Veritas Health Innovation, Melbourne, Australia. Available at www.covidence.org.
   Google Scholar
• Alhowaymel F, Abdelmalik MA, Mohammed AM, Mohamaed MO, Alenezi A. Reported side effects of COVID-19 vaccination among adults in Saudi Arabia: a cross-sectional study. SAGE Open Nurs. 2022;8:23779608221103210. doi:10.1177/23779608221103208.
   Web of Science ®Google Scholar
• Amodio E, Minutolo G, Casuccio A, Costantino C, Graziano G, Mazzucco W, Pieri A, Vitale F, Zarcone M, Restivo V. Adverse reactions to anti-SARS-CoV-2 vaccine: a Prospective Cohort study based on an active surveillance system. Vaccines (Basel). 2022;10(3):345. doi:10.3390/vaccines10030345.
   PubMed Web of Science ®Google Scholar
• Angkasekwinai N, Sewatanon J, Niyomnaitham S, et al. Comparison of safety and immunogenicity of CoronaVac and ChAdOx1 against the SARS-CoV-2 circulating variants of concern (alpha, Delta, beta) in Thai healthcare workers. Vaccine. 2022;10:100153. doi:https://dx.doi.org/10.1016/j.jvacx.2022.100153.
   Web of Science ®Google Scholar
• Azzolini E, Canziani LM, Voza A, et al. Short-term adverse events and antibody response to the BNT162b2 SARS-CoV-2 vaccine in 4156 Health care professionals. Vaccines (Basel). 2022;10(3):439. doi:https://dx.doi.org/10.3390/vaccines10030439.
   PubMed Web of Science ®Google Scholar
• Beatty AL, Peyser ND, Butcher XE, Cocohoba JM, Lin F, Olgin JE, Pletcher MJ, Marcus GM. Analysis of COVID-19 vaccine type and adverse effects following vaccination. JAMA Netw Open. 2021;4(12):e2140364. doi:10.1001/jamanetworkopen.2021.40364.
   PubMed Web of Science ®Google Scholar
• Bettinger JA, Sadarangani M, De Serres G, et al. Protocol: the Canadian National vaccine safety network: surveillance of adverse events following immunisation among individuals immunised with the COVID-19 vaccine, a cohort study in Canada. BMJ Open. 2022;12(1):51254. doi:10.1136/BMJOPEN-2021-051254.
   Web of Science ®Google Scholar
• Briggs FBS, Mateen FJ, Schmidt H, et al. COVID-19 vaccination reactogenicity in persons with multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2021;9(1). doi:10.1212/NXI.0000000000001104.
   PubMed Web of Science ®Google Scholar
• Bsoul EA, Loomer PM, Patel SKS. COVID-19 vaccination experience among United States dental professionals and students: safety, confidence, concerns, and side effects. PLoS One. 2022;17(2):e0264323. doi:10.1371/journal.pone.0264323.
   PubMed Web of Science ®Google Scholar
• Chalermphanchai N, Arunothong W, Jettavan N, et al. Safety, tolerability, and antibody response after intradermal vaccination of PFE-BNT in adults who have completed two-doses of verocell (inactivated vaccine). Vaccine. 2022;10:100148. doi:https://dx.doi.org/10.1016/j.jvacx.2022.100148.
   Web of Science ®Google Scholar
• Cuschieri S, Gauci C, Agius S, Grech V. Vaccine hesitancy among Maltese healthcare workers vis-a-vis influenza and COVID-19 vaccination. Malta Medical Journal. 2022;34(3):39–49. http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emexb&NEWS=N&AN=2017807278.
   Google Scholar
• d’Arminio Monforte A, Tavelli A, Perrone PM, et al. Association between previous infection with SARS CoV-2 and the risk of self-reported symptoms after mRNA BNT162b2 vaccination: data from 3,078 health care workers. EClinicalMedicine. 2021;36:100914. doi:10.1016/j.eclinm.2021.100914.
   PubMedGoogle Scholar
• Deng L, Glover C, Dymock M, et al. The short term safety of COVID-19 vaccines in Australia: AusVaxSafety active surveillance, February – August 2021. Med J Aust. 2022;217(4):195–202. doi:https://dx.doi.org/10.5694/mja2.51619.
   PubMed Web of Science ®Google Scholar
• Ebinger JE, Lan R, Sun N, et al. Symptomology following mRNA vaccination against SARS-CoV-2. Prev Med. 2021;153. doi:10.1016/J.YPMED.2021.106860.
   Web of Science ®Google Scholar
• Figueroa-Hurtado E, Ortiz-Farias DL, Sada-Ovalle I, Maldonado-Ortiz SY, Valdivieso-Jimenez JA, Cortes-Telles A. Humoral immune response in healthcare workers after two doses of a BNT162b2 mRNA vaccine in Yucatan, Mexico. Respirol Case Rep. 2022;10(4):e0920. doi:10.1002/rcr2.920.
   PubMed Web of Science ®Google Scholar
• Lai FTT, Chua GT, Chan EWW, et al. Adverse events of special interest following the use of BNT162b2 in adolescents: a population-based retrospective cohort study. Emerg Microbes Infect. 2022;11(1):885–893. doi:10.1080/22221751.2022.2050952.
   PubMed Web of Science ®Google Scholar
• Gepner Y, Mofaz M, Oved S, Yechezkel M, Constantini K, Goldstein N, Eisenkraft A, Shmueli E, Yamin D. Utilizing wearable sensors for continuous and highly-sensitive monitoring of reactions to the BNT162b2 mRNA COVID-19 vaccine. Commun Med. 2022;2(1):27. doi:10.1038/s43856-022-00090-y.
   PubMedGoogle Scholar
• Goldlin T, Kalyanaraman S, Ravichandran M, Ramya J. A pharmacovigilance study of covishield in a tertiary care teaching hospital in Tamil Nadu. J Pharmacol Pharmacother. 2021;12(3):131–136. doi:10.4103/jpp.jpp_63_21.
   Web of Science ®Google Scholar
• Guan G, Mofaz M, Qian G, Patalon T, Shmueli E, Yamin D, Brandeau ML. Higher sensitivity monitoring of reactions to COVID-19 vaccination using smartwatches. npj Digit Med. 2022;5(1):140. doi:10.1038/s41746-022-00683-w.
   PubMed Web of Science ®Google Scholar
• Hammad NM, Kadry HM, Malek MM, Bahgat SM, Abdelsalam NM, Afifi AHM, Abo-Alella DA. Maintenance of antibody response in Egyptian healthcare workers vaccinated with ChAdOx1 nCoV-19 vaccine during Delta and omicron variants pandemic: a Prospective study. Vaccines (Basel). 2022;10(10):1706. doi:https://dx.doi.org/10.3390/vaccines10101706.
   PubMed Web of Science ®Google Scholar
• Hyun J, Park Y, Song YG, et al. Reactogenicity and immunogenicity of the ChAdOx1 nCOV-19 coronavirus disease 2019 vaccine in South Korean healthcare workers. Yonsei Med J. 2022;63(12):1078–87. doi:10.3349/ymj.2022.0298.
   PubMed Web of Science ®Google Scholar
• Inoue S, Igarashi A, Morikane K, Hachiya O, Watanabe M, Kakehata S, Sato S, Ueno Y. Adverse reactions to BNT162b2 mRNA COVID-19 vaccine in medical staff with a history of allergy. Respir Investig. 2022;60(2):248–255. doi:10.1016/j.resinv.2021.11.007.
   PubMed Web of Science ®Google Scholar
• Javed D, Hadi Alharbi Y, Javed A, Iqbal J. Symptoms and side effects of the ChAdOx1 nCoV-19 vaccine (AZD1222) among healthcare workers. PJMHS. 2021;15(12):3202–3204. doi:10.53350/pjmhs2115123202.
   Google Scholar
• Jeon M, Kim J, Oh CE, Lee JY. Adverse events following immunization associated with the first and second doses of the chadox1 ncov-19 vaccine among healthcare workers in korea. Vaccines (Basel). 2021;9(10):1096. doi:10.3390/vaccines9101096.
   PubMed Web of Science ®Google Scholar
• Kim T, Park SY, Yu S, Park JW, Lee E, Jeon MH, Kim TH, Choo EJ.Impacts of side effects to bnt162b2 and the first dose of chadox1 anti‐sars‐cov‐2 vaccination on work productivity, the need for medical attention, and vaccine acceptance: a multicenter survey on healthcare workers in referral teaching hospitals in the republic of korea. Vaccines (Basel). 2021;9(6). doi:10.3390/VACCINES9060648/S1.
   Web of Science ®Google Scholar
• Lee GM, Romero JR, Bell BP. Postapproval vaccine safety surveillance for COVID-19 vaccines in the US. JAMA. 2020;324(19):1937–8. doi:10.1001/JAMA.2020.19692.
   PubMed Web of Science ®Google Scholar
• Levy I, Levin EG, Olmer L, et al. Correlation between adverse events and antibody titers among healthcare workers vaccinated with BNT162b2 mRNA COVID-19 vaccine. Vaccines (Basel). 2022;10(8):1220. doi:https://dx.doi.org/10.3390/vaccines10081220.
   PubMed Web of Science ®Google Scholar
• Lim SM, Chan HC, Santosa A, Quek SC, Liu EHC, Somani J. Safety and side effect profile of pfizer-BioNTech COVID-19 vaccination among healthcare workers: a tertiary hospital experience in Singapore. Ann Acad Med Singapore. 2021;50(9):703–11. doi:10.47102/ANNALS-ACADMEDSG.2021160.
   PubMed Web of Science ®Google Scholar
• Lotan I, Wilf-Yarkoni A, Friedman Y, Stiebel-Kalish H, Steiner I, Hellmann MA. Safety of the BNT162b2 COVID-19 vaccine in multiple sclerosis (MS): early experience from a tertiary MS center in Israel. Eur J Neurol. 2021;28(11):3742–8. doi:10.1111/ENE.15028.
   PubMed Web of Science ®Google Scholar
• Low JM, Lee LY, Ng YPM, Zhong Y, Amin Z. Breastfeeding mother and child clinical outcomes after COVID-19 vaccination. J Hum Lact. 2022;38(1):37–42. doi:10.1177/08903344211056522.
   PubMed Web of Science ®Google Scholar
• Maruyama A, Sawa T, Teramukai S, Katoh N. Adverse reactions to the first and second doses of Pfizer-BioNTech COVID-19 vaccine among healthcare workers. J Infect Chemother. 2022;28(7):934–942. doi:10.1016/j.jiac.2022.03.015.
   PubMed Web of Science ®Google Scholar
• Mofaz M, Yechezkel M, Guan G, Brandeau ML, Patalon T, Gazit S, Yamin D, Shmueli E. Self-reported and physiologic reactions to Third BNT162b2 mRNA COVID-19 (booster) vaccine dose. Emerg Infect Dis. 2022;28(7):1375–1383. doi:10.3201/eid2807.212330.
   PubMed Web of Science ®Google Scholar
• Nachtigall I, Bonsignore M, Hohenstein S, et al. Effect of gender, age and vaccine on reactogenicity and incapacity to work after COVID-19 vaccination: a survey among health care workers. BMC Infect Dis. 2022;22(1):291. doi:10.1186/s12879-022-07284-8.
   PubMed Web of Science ®Google Scholar
• Nittner-Marszalska M, Rosiek-Biegus M, Kopeć A, Pawłowicz R, Kosińska M, Łata A, Szenborn L. Pfizer-BioNTech COVID-19 vaccine tolerance in allergic versus non-allergic individuals. Vaccines (Basel). 2021;9(6):553. doi:10.3390/VACCINES9060553.
   PubMed Web of Science ®Google Scholar
• Okumura K, Hara A, Inada I, Sugiyama D, Hoshino T, Yakoh T, Yokoyama H, Urushihara H. Real-time survey of vaccine safety of the mRNA-1273 SARS-CoV-2 vaccine in workplace vaccination at Keio University. Vaccines (Basel). 2022;10(9):1461. doi:https://dx.doi.org/10.3390/vaccines10091461.
   PubMed Web of Science ®Google Scholar
• Park C, Sakong J, Jo S, Kim M, Baek K. Adverse effects on work and daily life interference among healthcare workers after the first and second chadox1 and bnt162b2 COVID-19 vaccine doses. Vaccines (Basel). 2021;9(8):926. doi:10.3390/vaccines9080926.
   PubMed Web of Science ®Google Scholar
• Pellegrino R, Pellino G, Selvaggi L, Selvaggi F, Federico A, Romano M, Gravina AG. 2022. BNT162B2 MRNA COVID-19 vaccine safety in inflammatory bowel disease patients on biologic therapy: a monocentric real-world study. United European Gastroenterol J. 10(Supplement 8):1088. doi:10.1002/ueg2.12290.
   Google Scholar
• Presby DM, Capodilupo ER. Biometrics from a wearable device reveal temporary effects of COVID-19 vaccines on cardiovascular, respiratory, and sleep physiology. J Appl Physiol. 2022;132(2):448–458. doi:10.1152/japplphysiol.00420.2021.
   PubMed Web of Science ®Google Scholar
• Rahmani A, Dini G, Orsi A, et al. Reactogenicity of BNT162b2 mRNA COVID-19 vaccine in a Young Working age population: a survey among Medical School residents, within a Mass vaccination campaign, in a regional reference teaching Hospital in Italy. Vaccines (Basel). 2021;9(11):1269. doi:10.3390/VACCINES9111269.
   PubMed Web of Science ®Google Scholar
• Rolfes L, Harmark L, Kant A, Van Balveren L, Van Hunsel F. Cohort event monitoring of COVID-19 vaccine reactogenicity in the Netherlands using patient reported outcomes. Drug Saf. 2021;44(12):1418–1419. doi:10.1007/s40264-021-01129-0.
   Web of Science ®Google Scholar
• Sadarangani M, Soe P, Shulha P, et al. Safety of COVID-19 vaccines in pregnancy: a Canadian National vaccine safety (CANVAS) network cohort study. Lancet Infect Dis. 2022;22(11):1553–1564. doi:https://dx.doi.org/10.1016/S1473-3099(22)00426-1.
   PubMed Web of Science ®Google Scholar
• Sen P, R N, Nune A, et al. POS1260 COVID-19 vaccination-related adverse events among autoimmune disease patients: results from the COVID-19 vaccination in autoimmune diseases (COVAD) study. Ann Rheum Dis. 2022;81(Suppl 1):966–967. doi:https://dx.doi.org/10.1136/annrheumdis-2022-eular.4197.
   Google Scholar
• Shimamura Y, Anbo Y, Furuta Y. Post-vaccination adverse reactions after receiving the Pfizer-BioNTech coronavirus disease 2019 vaccines among healthcare workers in Sapporo, Japan. Cureus. 2022;14(3):e23549. doi:10.7759/cureus.23549.
   PubMed Web of Science ®Google Scholar
• Song JE, Oh GB, Park HK, Lee SS, Kwak YG. Survey of adverse events after the First dose of the ChAdOx1 nCoV-19 vaccine: a single-center experience in Korea. Infect Chemother. 2021;53(3):557. doi:10.3947/IC.2021.0044.
   PubMed Web of Science ®Google Scholar
• Supangat, Sakinah EN, Nugraha MY, Qodar TS, Mulyono BW, Tohari AI. COVID-19 vaccines programs: adverse events following immunization (AEFI) among medical clerkship Student in Jember, Indonesia. BMC Pharmacol Toxicol. 2021;22(1). doi:10.1186/S40360-021-00528-4.
   PubMed Web of Science ®Google Scholar
• Tani N, Ikematsu H, Goto T, et al. Correlation of post-vaccination fever with specific antibody response to SARS-CoV-2 BNT162b2 booster and no significant influence of antipyretic medication. medRxiv. Published online 2022. doi:10.1101/2022.07.25.22277569.
   Google Scholar
• Tawinprai K, Siripongboonsitti T, Porntharukchareon T, Dechates B, Monprach H, Sornsamdang G, Wittayasak K, Soonklang K, Mahanonda N. Persistence of immunogenicity, contributing factors of an immune response, and reactogenicities after a single dose of the ChAdOx1 (AZD1222) COVID-19 vaccine in the Thai population. Hum Vaccin Immunother. 2022;18(1):2035573. doi:10.1080/21645515.2022.2035573.
   PubMed Web of Science ®Google Scholar
• Toussia-Cohen S, Yinon Y, Peretz-Machluf R, et al. Early adverse events and immune response Following Second and Third COVID-19 vaccination in pregnancy. J Clin Med. 2022;11(16):4720. doi:10.3390/jcm11164720.
   PubMed Web of Science ®Google Scholar
• Vigezzi GP, Lume A, Minerva M, Nizzero P, Biancardi A, Gianfredi V, Odone A, Signorelli C, Moro M. Safety surveillance after BNT162b2 mRNA COVID-19 vaccination: results from a cross-sectional survey among staff of a large Italian teaching hospital. Acta Biomed. 2021;92(S6). doi:10.23750/ABM.V92IS6.12217.
   Google Scholar
• Walmsley S, Szadkowski L, Wouters B, et al. Safety and efficacy of preventative COVID vaccines: the StopCoV study.medRxiv. Published online 2022. doi: 10.1101/2022.02.09.22270734.
   Google Scholar
• Warkentin L, Zeschick N, Kuhlein T, Steininger P, Überla K, Kaiser I, Gall C, Sebastião M, Hueber S. Reactogenicity after heterologous and homologous COVID-19 prime-boost vaccination regimens: descriptive interim results of a comparative observational cohort study. BMC Infect Dis. 2022;22(1):504. 0531. doi: 10.1186/s12879-022-07443-x.
   PubMed Web of Science ®Google Scholar
• Wei Y, Wang Y, Liu J, et al. Investigation of adverse events experienced by healthcare workers following immunization with Homologous orHeterologous COVID-19 booster vaccinations. Vaccines (Basel). 2022;10(11):1869. doi:https://dx.doi.org/10.3390/vaccines10111869. 1104.
   PubMed Web of Science ®Google Scholar
• Yamazaki S, Watanabe K, Okuda Y, et al. Adverse effect investigation using application software after vaccination against SARS-CoV-2 for healthcare workers. Journal of Infection and Chemotherapy. 2022;28(6):791–796. doi:https://dx.doi.org/10.1016/j.jiac.2022.02.020. 0301.
   PubMed Web of Science ®Google Scholar
• Yechezkel M, Mofaz M, Painsky A, Patalon T, Gazit S, Shmueli E, Yamin D. Safety of the fourth COVID-19 BNT162b2 mRNA (second booster) vaccine: a prospective and retrospective cohort study. Lancet Respir Med. 2023;11(2):139–150. Published online 20221118. doi: https://dx.doi.org/10.1016/S2213-2600(22)00407-6.
   PubMed Web of Science ®Google Scholar
• Zhang MX, Zhang TT, Shi GF, Cheng F-M, Zheng Y-M, Tung T-H, Chen H-X. Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China. Expert Rev Vaccines. 2021;20(7):891–898. doi:10.1080/14760584.2021.1925112.
   PubMed Web of Science ®Google Scholar
• Zhu JS, Zhang MX, Chien CW, Yang W-Y, Shi G-F, Qiu S, Tung T-H, Chen H-X. Sex differences in adverse reactions to an inactivated SARS-CoV-2 vaccine among Medical staff in China. Front Med. 2021;8:731593. doi:10.3389/FMED.2021.731593/FULL.
   PubMed Web of Science ®Google Scholar
• Wilson K, McDougall C, Upshur R. The new international Health Regulations and the federalism dilemma. PLoS Med. 2006;3(1):30–34. doi:10.1371/JOURNAL.PMED.0030001.
   Web of Science ®Google Scholar
• Straus W, Rubin H. COVID-19 vaccine safety monitoring in low and middle income countries – time for a bold new approach. Vaccine. 2022;40(32):4301. doi:10.1016/J.VACCINE.2022.06.053.
   PubMed Web of Science ®Google Scholar
• Buttery JP, Clothier H. Information systems for vaccine safety surveillance. Hum Vaccin Immunother. 2022;18(6). doi:10.1080/21645515.2022.2100173.
   Web of Science ®Google Scholar
• Harris T, Nair J, Fediurek J, Deeks SL. Assessment of sex-specific differences in adverse events following immunization reporting in Ontario, 2012–15. Vaccine. 2017;35(19):2600–4. doi:10.1016/J.VACCINE.2017.03.035.
   PubMed Web of Science ®Google Scholar
• Klok FA, Pai M, Huisman MV, Makris M. Vaccine-induced immune thrombotic thrombocytopenia. Lancet Haematol. 2022;9(1):e73–e80. doi:10.1016/S2352-3026(21)00306-9.
   PubMed Web of Science ®Google Scholar
• Wong HL, Hu M, Zhou CK, et al. Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases. Lancet. 2022;399(10342):2191–9. doi:10.1016/S0140-6736(22)00791-7.
   PubMed Web of Science ®Google Scholar
• WHO. Performance indicators. Accessed June 26, 2023. https://www.who.int/groups/global-advisory-committee-on-vaccine-safety/topics/aefi/performance-indicators
   Google Scholar
• Kohl KS, Bonhoeffer J, Braun MM, Chen RT, Duclos P, Heijbel H, Heininger U, Loupi E, Marcy SM. The brighton collaboration: creating a global standard for case definitions (and guidelines) for adverse events following immunization. Advances in Patient Safety: From Research to Implementation (Volume 2: Concepts and Methodology). Published online 2005. Accessed November 14, 2023. https://www.ncbi.nlm.nih.gov/books/NBK20507/
   Google Scholar
• Gold MS, Gidudu J, Erlewyn-Lajeunesse M, Law B. Can the Brighton collaboration case definitions be used to improve the quality of adverse event following immunization (AEFI) reporting?: anaphylaxis as a case study. Vaccine. 2010;28(28):4487–98. doi:10.1016/J.VACCINE.2010.04.041.
   PubMed Web of Science ®Google Scholar
• Psihogios A, Brianne Bota A, Mithani SS, Greyson D, Zhu DT, Fung SG, Wilson SE, Fell DB, Top KA, Bettinger JA, et al. A scoping review of active, participant-centred, digital adverse events following immunization (AEFI) surveillance: a Canadian immunization research network study. Vaccine. 2022;40(31):4065–80. doi:10.1016/J.VACCINE.2022.04.103.
   PubMed Web of Science ®Google Scholar